Combination therapy for locally advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests whether combining a targeted drug (surufatinib) and an immunotherapy (serplulimab) with standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery, compared to chemotherapy alone. It aims to improve the chance of successful removal of the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer that cannot be removed by surgery, but it has not spread far away.
- You are between 18 and 75 years old.
- You are generally healthy enough to carry out daily activities (able to care for yourself and walk around).
- Your organs (heart, lungs, liver, kidneys, bone marrow) are working well enough based on blood tests.
- You have not had prior chemotherapy, radiation, or other cancer treatment for this pancreatic cancer.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
This trial tests a new combination of drugs (including an oral targeted therapy and an immunotherapy) given before surgery for pancreatic cancer that is hard to remove or has high-risk features. The goal is to shrink the tumor to make surgery more likely to be successful.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.